HealthEquity (HQY) Q1 Earnings and Revenues Miss Estimates
HealthEquity, Inc. HQY reported adjusted earnings per share (EPS) of 43 cents in first-quarter fiscal 2021, which missed the Zacks Consensus Estimate of 44 cents by 2.3%. The bottom line was flat on a year-over-year basis.
Revenues in Detail
Thecompany generated revenues of $190 million, missing the Zacks Consensus Estimate by 1.3%. However, the figure skyrocketed 118% from the prior-year quarter.
HSA Member Detail
As of Apr 30, 2020, the total number of Health Savings Accounts (HSA), for which HealthEquity served as a non-bank custodian (HSA members), was 5.4 million, up 33% year over year.
Additionally, total Active HSA assets were $11.5 billion, up 38% year over year.
Total Accounts, including HSAs and complementary CDB accounts, came in at 12.7 million, up 169% year over year.
Segmental Performance
Service Revenues: At this segment, revenues totaled $111.3 million, up 315.3% from the year-ago figure.
Custodial Revenues: At this segment, revenues grew 11.9% year over year to $46.9 million.
Interchange Revenues: At this segment, revenues soared 73.8% year over year to $31.8 million.
HealthEquity, Inc. Price, Consensus and EPS Surprise
HealthEquity, Inc. price-consensus-eps-surprise-chart | HealthEquity, Inc. Quote
Margin Details
HealthEquity generated gross profit of $108.1 million, up 87.1% from the year-ago quarter. Gross margin was 56.9% of net revenues, down 947 bps year over year.
Adjusted operating profit in the fiscal first quarter was $46.5 million, up 59.6% year over year. Adjusted operating margin totaled 24.5% in the quarter, contracting 901 bps year over year.
Guidance
Due to uncertainty regarding the impact of the COVID-19 pandemic, the company is withdrawing its fiscal 2021 guidance.
For the fiscal second quarter, the company expects revenues between $168 million and $173 million. The Zacks Consensus Estimate for the same is pegged at $190.7 million.
Adjusted net income is projected between $17 million and $22 million.
Adjusted EPS is expected within 23-30 cents. The Zacks Consensus Estimate for earnings is pegged at 45 cents.
Summing Up
HealthEquity exited first-quarter of fiscal 2021 on a dull note. Nonetheless, the company witnessed strong growth in Service, Custodial and Interchange segments. Notably, solid growth in HSAs and custodial assets bolstered the top line. Currently, HealthEquity is the second-largest HSA custodian by market share. In addition to HSA, the company offers health reimbursement arrangement and health flexible spending account to regional employers. HealthEquity expedited its integration efforts (WageWorks buyout that closed on Aug 30, 2019) and now anticipates to achieve the previously announced goal of $50 million in run rate synergies, including the on-shoring of all telephone-based member services to the United States, by the end of the fiscal second quarter.
However, a significant drop in adjusted operating and gross margin raises concern. The company also faces stiff competition in the Medical Services market. HealthEquity is required to comply with the strict treasury regulations formulated by the Internal Revenue Service.
Zacks Rank and Key Picks
HealthEquity currently carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical space are Aphria Inc. APHA, Biogen Inc. BIIB and Eli Lilly and Company LLY.
Aphria reported third-quarter fiscal 2020 adjusted EPS of 2 cents against the Zacks Consensus Estimate of a loss of 4 cents. Net revenues of $64.4 million outpaced the consensus estimate by 14.6%. The company carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Biogen currently carries a Zacks Rank #2. It reported first-quarter 2020 adjusted EPS of $9.14, surpassing the Zacks Consensus Estimate by 18.1%. Revenues of $3.53 billion outpaced the consensus mark by 3.2%.
Eli Lilly delivered first-quarter 2020 EPS of $1.75, outpacing the Zacks Consensus Estimate by 12.9%. Revenues of $145.3 million surpassed the consensus estimate by 6.3%. The company currently sports a Zacks Rank #1.
Zacks Top 10 Stocks for 2020
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2020?
Last year's 2019 Zacks Top 10 Stocks portfolio returned gains as high as +102.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2020 today >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Biogen Inc. (BIIB) : Free Stock Analysis Report
Eli Lilly and Company (LLY) : Free Stock Analysis Report
HealthEquity, Inc. (HQY) : Free Stock Analysis Report
Aphria Inc. (APHA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
